Tuberculosis cases are ‘rising' in Mecklenburg County
Tuberculosis is on the rise in Mecklenburg County, but health officials say the overall risk to the public is still low.
Channel 9 learned Friday that there are currently 31 reported cases of active TB in Mecklenburg County residents.
TB is a bacterial infection that affects the lungs. It can cause coughing, weight loss, night sweats, fever, and other symptoms, though the disease is treatable with antibiotics.
Mecklenburg County Public Health told Channel 9 that some cases have been linked, but they're not responding to any official outbreaks or 'large-scale contact investigations.'
Public health officials said you can reduce the risk of TB infection by limiting close contact with people who are diagnosed with active TB, washing your hands frequently, and covering your mouth when you cough or sneeze.
North Carolina is also seeing an increase in emergency department visits for respiratory viruses. As of last week, 19.6% of all emergency room visits had symptoms of respiratory virus. You can see the state's statistics at this link.
(VIDEO: Tuberculosis case reported at SC high school, health officials confirm)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
Union County family escapes house fire; community rallies to help rebuild
A Union County family is safe but lost everything in a house fire investigators say started with an air compressor and now, neighbors are stepping in to support them as they start over. ALSO READ: Union County family's home catches fire months after kids hit by truck Channel 9's Erika Jackson spoke with the family as they get support from neighbors along Haden Drive off New Town Road near Waxhaw. The Union County Fire Marshal ruled it an accident. Investigators believe an air compressor was plugged into one car, pumping air into a tire on a pickup truck, which started the fire. Everything the Robinsons own is gone. 'Material things can be replaced but someone's life can't,' said Veronica Robinson. Robinson sees beyond the damage. 'All I can think about is my mom,' she said. 'All I can think about is her. What if I lost her?' Robinson said she was in her bathroom Monday morning when she heard a visiting family member banging on the door. 'I saw that the flames were starting to jump onto the house,' Robinson said. 'And when I [had] seen that, I immediately ran back in the house, ran to that room right there, and got my mom out.' Robinson said her daughter-in-law helped her oxygen-dependent father escape. He's recovering in a hospital as her family works to figure out what's next. 'I'd be completely lost if it wasn't for the community coming together and just helping any way they can anyway,' Robinson said. She credits her neighbor, Kristen Marcum, for calling 911 and coordinating donations through a GoFundMe account. Robinson said she was reminded of what she does have. 'This has really taught me what paying it forward means and just taught me to slow down and smell the roses,' she said. The Red Cross is helping them with temporary housing. She's waiting for her renters and car insurance to come through. GoFundMe for the Robinsons VIDEO: Dilworth fire that led to explosion set intentionally
Yahoo
15 hours ago
- Yahoo
TerThera reached GMP status for their Terbium-161 product, improving clinical access by meeting the highest quality standards.
GMP TERBIUM-161 PRODUCT LAUNCHED BY TERTHERA BREDA, Netherlands, June 5, 2025 /PRNewswire/ -- TerThera B.V. has officially launched the world's first GMP-compliant Terbium-161 NCA, setting a new benchmark in the commercial scale production of this promising radionuclide. Now, with the successful implementation of European Good Manufacturing Practices (GMP), TerThera's Terbium-161 meets the highest quality and safety standards required for clinical trials and patient care across Europe and beyond. This lowers regulatory barriers and accelerates the path to new therapies providing hospitals, clinicians, and researchers immediate access to this next-generation therapeutic radionuclide Terbium-161. A New Era in Cancer Treatment Terbium-161 NCA is a no-carrier-added, neutron-activated radionuclide uniquely suited for Radio Ligand Therapy (RLT). With an abundant emission of Auger electrons and high Linear Energy Transfer (LET), combined with similar chemical characteristics to well-known radiolanthanides, Tb-161 brings a high potential to decimate both primary tumors and (micro) metastases. When paired with proven targeting vectors like PSMA, SST, and FAPI analogues, Tb-161 demonstrates a bioequivalence while significantly increasing absorbed doses in all lesions, offering novel treatment options and strategies in cancer healthcare, improving the overall disease control and may even overcome radio-resistant disease. Global Vision, Local Innovation "This milestone is more than a regulatory achievement—it's a leap forward in our mission to bring Terbium-161 to patients worldwide," said Philippe van Overeem, CEO of TerThera. "GMP Terbium-161 is now a clinical reality, and this is just the beginning. We are actively constructing a large-scale production facility to meet the growing global demand and expand access to this promising radionuclide for optimized cancer treatments." With this launch, TerThera reaffirms its commitment to transforming the landscape of radiopharmaceuticals and leading the charge in precision oncology. About TerThera BV TerThera is a radionuclide production-focused company based in The Netherlands. The founders and staff of TerThera have decades of experience in the nuclear medicine industry and are highly dedicated to bringing the innovative radionuclide Terbium-161 (Tb-161) to the clinic. TerThera is building a global platform including GMP production facilities in Europe, USA and Asia to meet the growing demand for radionuclides in RLT. support@ View original content: SOURCE TerThera Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Tuberculosis Therapeutics Market Opportunity, and Forecasts Report 2025-2030: Next-Gen Drug Development Demands, Cost Efficiency, Regulatory Agility, and Strategic Partnerships Influence on Growth
The Tuberculosis Therapeutics Market is driven by rising drug-resistant TB and persistent global demand. Opportunities include developing innovative, cost-effective TB drugs with shorter, more effective regimens. Companies can gain a competitive edge through strategic collaborations and navigating regulatory barriers. Tuberculosis Therapeutics Market Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Tuberculosis Therapeutics Market was valued at USD 2.18 Billion in 2024, and is expected to reach USD 2.94 Billion by 2030, rising at a CAGR of 5.05% Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions. With next-generation drug development - particularly in second-line therapies - on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge. Key Market Drivers High Global Burden of TuberculosisThe global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability. For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial Market Challenges Inadequate Funding and Limited Commercial Incentives for Drug DevelopmentThe concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low. Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical Market Trends Shift Toward Shorter, More Effective Treatment RegimensThere is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.18 Billion Forecasted Market Value (USD) by 2030 $2.94 Billion Compound Annual Growth Rate 5.0% Regions Covered Global Report Scope Key Market Players AstraZeneca PLC Johnson & Johnson Services, Inc. Eli Lilly and Company Mylan Inc. Teva Pharmaceutical Industries Ltd Sanofi Novartis AG Sun Pharmaceutical Industries Ltd Pfizer Inc. Tuberculosis Therapeutics Market, By Disease Type: Active TB Latent TB Tuberculosis Therapeutics Market, By Therapy: First-Line Therapy Second-Line Therapy Tuberculosis Therapeutics Market, By Route of Administration: Oral Parenteral Others Tuberculosis Therapeutics Market, By Dosage Form: Tablets Capsules Injection Others Tuberculosis Therapeutics Market, By Distribution Channel: Hospital Pharmacy Retail Pharmacy Online Pharmacy Tuberculosis Therapeutics Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Tuberculosis Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
